Search | OpenScholar

Search results

1502 results found

ZNF281 enhances cardiac reprogramming by modulating cardiac and inflammatory gene expression.

Publication: Journal Article

Zhou, Huanyu, Maria Gabriela Morales, Hisayuki Hashimoto, Matthew E Dickson, Kunhua Song, Wenduo Ye, Min S Kim, et al. 2017. “ZNF281 Enhances Cardiac Reprogramming by Modulating Cardiac and Inflammatory Gene Expression.”. Genes & Development 31 (17): 1770-83.

High-efficiency reprogramming of fibroblasts into cardiomyocytes requires suppression of pro-fibrotic signalling.

Publication: Journal Article

Zhao, Yuanbiao, Pilar Londono, Yingqiong Cao, Emily J Sharpe, Catherine Proenza, Rebecca O’Rourke, Kenneth L Jones, et al. 2015. “High-Efficiency Reprogramming of Fibroblasts into Cardiomyocytes Requires Suppression of Pro-Fibrotic Signalling.”. Nature Communications 6: 8243.

Truman Roland

Person: PhD student

I am a graduate student pursuing a PhD in medical sciences at the Morsani College of Medicine (MCOM)). I earned my B.S. in biomedical engineering from USF in 2023 where I specialized in tissue engineering and wound healing. Now, I apply these tissue engineering techniques to the regeneration of the...

Novel Gottingen miniswine model of heart failure with preserved ejection fraction integrating multiple comorbidities

Publication: Journal Article

Sharp, TE., A. Scarborough, Z. Li, DJ. Polhemus, H. Hidalgo, JD. Schumacher, TR. Matsuura, et al. 2022. “Novel Gottingen Miniswine Model of Heart Failure With Preserved Ejection Fraction Integrating Multiple Comorbidities”. JACC: Basic to Translational Science.

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment. 2023 Jul 7;9:100212. doi: 10.1016/j.prdoa.2023.100212. eCollection 2023. PMID: 37497384

Publication: Journal Article

Isaacson, SH, RA Hauser, R Pahwa, D Gray, and S Duvvuri. 2023. “Dopamine Agonists in Parkinson’s Disease: Impact of D1-Like or D2-Like Dopamine Receptor Subtype Selectivity and Avenues for Future Treatment. 2023 Jul 7;9:100212. Doi: 10.1016/J.prdoa.2023.100212. ECollection 2023. PMID: 37497384”. Clin Park Relat Disord.

Istradefylline - a first generation adenosine A2A antagonist for the treatment of Parkinson's disease. Expert Rev Neurother 2021;21:317-333.

Publication: Journal Article

Jenner, P, A Mori, SD Aradi, and RA Hauser. 2021. “Istradefylline - a First Generation Adenosine A2A antagonist for the Treatment of Parkinson’s Disease. Expert Rev Neurother 2021;21:317-333.”. Expert Rev Neurother.

Get in Touch

Page

Powerful websites to share your science story: from team and research to publications and impact.

Expanding phenotype with severe midline brain anomalies and missense variant supports a causal role for FOXA2 in 20p11.2 deletion syndrome. American journal of medical genetics. Part A, 179(9), 1783–1790.

Publication: Journal Article

“Expanding Phenotype With Severe Midline Brain Anomalies and Missense Variant Supports a Causal Role for FOXA2 in 20p11.2 Deletion Syndrome. American Journal of Medical Genetics. Part A, 179(9), 1783–1790.”. 2019. American Journal of Medical Genetics.

Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol 2019;18:145-154.

Publication: Journal Article

LeWitt, PA, RA Hauser, R Pahwa, SH Isaacson, HH Fernandez, M Lew, M Saint-Hilaire, et al. 2019. “Safety and Efficacy of CVT-301 (levodopa Inhalation Powder) on Motor Function During off Periods in Patients With Parkinson’s Disease: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial. Lancet Neurol 2019;18:145-154.”. Lancet Neurol.

Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease. Parkinsonism Relat Disord 2019;64:175-180.

Publication: Journal Article

Hauser, RA, SH Isaacson, A Ellenbogen, BE Safirstein, DD Truong, SF Komjathy, DM Kegler-Ebo, P Zhao, and C Oh. 2019. “Orally Inhaled Levodopa (CVT-301) for Early Morning OFF Periods in Parkinson’s Disease. Parkinsonism Relat Disord 2019;64:175-180.”. Parkinsonism Relat Disord.